Weiguang Xue

Vice President
Weiguang Xue



M.Sc., international health policy (health economics), London School of Economics; B.A., international economics and trade, Zhejiang Gongshang University

Summary of Experience

Mr. Xue consults on cases involving health economics and outcomes research (HEOR). He specializes in using health economics analyses to inform product launch strategies, as well as decision making in early-stage clinical development. Mr. Xue has extensive experience in the economic evaluation of health technologies across multiple therapeutic areas, including oncology, infectious diseases, autoimmune diseases, central nervous system diseases, ophthalmology, and gynecology. His work includes cost-effectiveness analysis, budget impact analysis, systematic literature review, indirect treatment comparison, evaluation of health care resource use, global value dossier, and market access strategy. He has led successful health technology assessment (HTA) submissions to the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and the All Wales Medicines Strategy Group (AWMSG). He has also developed global economic models across multiple indications and led country rollouts supporting market access in Europe, North America, and Asia.